Zacks Research Brokers Lower Earnings Estimates for Chemours

Key Points

• Zacks Research has downgraded Chemours' Q3 2025 earnings per share (EPS) forecast from $0.48 to $0.33, indicating a deterioration in expected performance.
• Despite a recent quarterly earnings beat, Chemours reported a negative net margin of 7.19% and has set a full-year earnings estimate of $2.03 per share.
• The company also announced a quarterly dividend of $0.0875, representing a yield of 2.3%, although its dividend payout ratio is currently negative at -12.50%.

The Chemours Company (NYSE:CC - Free Report) - Zacks Research decreased their Q3 2025 earnings per share (EPS) estimates for shares of Chemours in a research report issued to clients and investors on Monday, August 18th. Zacks Research analyst Team now anticipates that the specialty chemicals company will earn $0.33 per share for the quarter, down from their prior forecast of $0.48. The consensus estimate for Chemours' current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours' Q1 2026 earnings at $0.37 EPS, Q2 2026 earnings at $0.66 EPS, Q3 2026 earnings at $0.77 EPS, FY2026 earnings at $2.20 EPS and FY2027 earnings at $2.62 EPS.

Chemours (NYSE:CC - Get Free Report) last released its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, beating analysts' consensus estimates of $0.46 by $0.12. The business had revenue of $1.62 billion during the quarter, compared to the consensus estimate of $1.57 billion. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The firm's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.38 earnings per share. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

A number of other research firms also recently weighed in on CC. The Goldman Sachs Group decreased their target price on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a research report on Wednesday, May 14th. Barclays cut their price objective on Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, May 28th. Wall Street Zen downgraded Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. UBS Group cut their price objective on Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Mizuho increased their price objective on Chemours from $13.00 to $16.00 and gave the company an "outperform" rating in a report on Tuesday, July 15th. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, Chemours currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.38.

Chemours Stock Down 1.0%

Chemours stock traded down $0.1550 during mid-day trading on Wednesday, reaching $15.2150. The company's stock had a trading volume of 820,745 shares, compared to its average volume of 3,567,232. The company has a market capitalization of $2.28 billion, a price-to-earnings ratio of -5.44 and a beta of 1.61. Chemours has a 12 month low of $9.13 and a 12 month high of $22.38. The business's 50 day simple moving average is $12.90 and its 200 day simple moving average is $12.88. The company has a debt-to-equity ratio of 17.16, a quick ratio of 0.83 and a current ratio of 1.68.

Chemours Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 15th will be issued a dividend of $0.0875 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.35 annualized dividend and a dividend yield of 2.3%. Chemours's payout ratio is presently -12.50%.

Insider Activity

In related news, CEO Denise Dignam bought 4,068 shares of Chemours stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average price of $12.06 per share, with a total value of $49,060.08. Following the acquisition, the chief executive officer owned 191,546 shares of the company's stock, valued at approximately $2,310,044.76. This represents a 2.17% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Damian Gumpel bought 7,822 shares of Chemours stock in a transaction that occurred on Tuesday, June 3rd. The shares were bought at an average cost of $9.95 per share, with a total value of $77,828.90. Following the acquisition, the insider directly owned 131,701 shares in the company, valued at $1,310,424.95. This trade represents a 6.31% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 25,290 shares of company stock valued at $250,437 in the last ninety days. 0.47% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CC. Wells Fargo & Company MN increased its position in Chemours by 7.0% during the 4th quarter. Wells Fargo & Company MN now owns 84,369 shares of the specialty chemicals company's stock worth $1,426,000 after buying an additional 5,540 shares during the period. Raymond James Financial Inc. bought a new position in Chemours during the 4th quarter worth $2,283,000. Sterling Capital Management LLC increased its position in Chemours by 54.8% during the 4th quarter. Sterling Capital Management LLC now owns 8,453 shares of the specialty chemicals company's stock worth $143,000 after buying an additional 2,991 shares during the period. Barclays PLC increased its position in Chemours by 41.7% during the 4th quarter. Barclays PLC now owns 152,433 shares of the specialty chemicals company's stock worth $2,576,000 after buying an additional 44,884 shares during the period. Finally, Guggenheim Capital LLC increased its position in Chemours by 90.8% during the 4th quarter. Guggenheim Capital LLC now owns 44,421 shares of the specialty chemicals company's stock worth $751,000 after buying an additional 21,137 shares during the period. Institutional investors own 76.26% of the company's stock.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.